Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

OptimizeRx (OPRX) Shares Outstanding (Diluted Average) (2017 - 2026)

OptimizeRx's Shares Outstanding (Diluted Average) history spans 15 years, with the latest figure at $19.0 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 3.86% to $19.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.0 million, a 3.86% increase, with the full-year FY2025 number at $19.0 million, up 3.86% from a year prior.
  • Shares Outstanding (Diluted Average) hit $19.0 million in Q4 2025 for OptimizeRx, down from $19.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for OPRX hit a ceiling of $19.5 million in Q3 2025 and a floor of $16.1 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $17.8 million across 5 years, with a median of $18.0 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 23.68% in 2021 and later dropped 7.47% in 2023.
  • Tracing OPRX's Shares Outstanding (Diluted Average) over 5 years: stood at $17.7 million in 2021, then rose by 0.53% to $17.8 million in 2022, then dropped by 3.71% to $17.1 million in 2023, then increased by 6.82% to $18.3 million in 2024, then increased by 3.86% to $19.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for OPRX at $19.0 million in Q4 2025, $19.5 million in Q3 2025, and $18.5 million in Q2 2025.